MOONLAKE IMMUNOTHERAPEUTICS
MLTXNASDAQTrading Snapshot
- Day Range
- $16.48 – $16.67
- 52-Week Range
- $5.95 – $62.75
- Volume
- $1.57B
- Avg Volume
- $1.78B
- Shares Outstanding
- 82.6M
- Next Earnings
- Sep 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $225M
- Last Q Revenue
- $52M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-3.87
- Dividend Yield
- —
Why Investors Own MLTX
- ✓High-growth profile — revenue up +24.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 41% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About MOONLAKE IMMUNOTHERAPEUTICS
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study
MoonLake Immunotherapeutics (MLTX) announces positive Phase 3 psoriatic arthritis trial results. Cash runway backed through mid-2028.
MoonLake Immunotherapeutics Reports Topline Results From Phase 3 IZAR-1 Trial Showing Sonelokimab Met All Week 16 Endpoints In Biologic‑Naïve Psoriatic Arthritis Patients
Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with induction, and
MoonLake Q2 EPS $(0.84) Beats $(0.93) Estimate
MoonLake (NASDAQ:MLTX) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.93) by 9.68 percent. This is a 3.45 percent increase over losses of $(0.87) per share from the same
HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $45 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $45 price target.